TY - JOUR
T1 - The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway
AU - Sareddy, Gangadhara Reddy
AU - Geeviman, Khamushavalli
AU - Ramulu, Chinta
AU - Babu, Phanithi Prakash
N1 - Funding Information:
Acknowledgments We greatly acknowledge the Professor P. Red-danna (University of Hyderabad, India) for providing celecoxib. DBT, DST, CSIR, and ICMR are acknowledged for funding the laboratory, and CSIR, New Delhi, India (fellowship to GRS) is also acknowledged. We acknowledge Dr Syed Maqbool Ahmed, in charge of the CIL facility, UoH, and technical assistance of Miss Nalini for the confocal microscopy.
PY - 2012/1
Y1 - 2012/1
N2 - Gliomas are devastating primary tumors of the central nervous system and tend to recur even after standard therapy. Celecoxib, the selective COX-2 nonsteroidal anti-inflammatory drug, has anti-neoplastic activity against several malignancies. Accumulating evidence suggests that several COX-2-independent mechanisms may also be involved in the anti-tumor effects of celecoxib. Deregulation of the NF-κB signaling pathway contributes to enhanced glioma cell survival, proliferation, and chemoresistance. In this study, we examined the efficacy of celecoxib in suppressing the growth of glioblastoma cell lines. We observed that treatment with celecoxib significantly reduced the proliferation of a variety of GBM cell lines in a dose-dependent manner and also induced apoptosis, which was evident from enhanced caspase-3 and 8 activity, PARP cleavage, and TUNEL positive cells. Celecoxib treatment significantly down-regulated TNF-α induced NF-κB nuclear translocation, NF-κB DNA binding activity, and NF-κB-dependent reporter gene expression in U373 and T98G cells in a dose-dependent manner. Furthermore, celecoxib suppressed IκBα degradation and phosphorylation and reduced IKK activity in a dose-dependent manner. This study provides evidence that celecoxib suppresses the growth of GBM cell lines partly by inhibiting the NF-κB signaling pathway.
AB - Gliomas are devastating primary tumors of the central nervous system and tend to recur even after standard therapy. Celecoxib, the selective COX-2 nonsteroidal anti-inflammatory drug, has anti-neoplastic activity against several malignancies. Accumulating evidence suggests that several COX-2-independent mechanisms may also be involved in the anti-tumor effects of celecoxib. Deregulation of the NF-κB signaling pathway contributes to enhanced glioma cell survival, proliferation, and chemoresistance. In this study, we examined the efficacy of celecoxib in suppressing the growth of glioblastoma cell lines. We observed that treatment with celecoxib significantly reduced the proliferation of a variety of GBM cell lines in a dose-dependent manner and also induced apoptosis, which was evident from enhanced caspase-3 and 8 activity, PARP cleavage, and TUNEL positive cells. Celecoxib treatment significantly down-regulated TNF-α induced NF-κB nuclear translocation, NF-κB DNA binding activity, and NF-κB-dependent reporter gene expression in U373 and T98G cells in a dose-dependent manner. Furthermore, celecoxib suppressed IκBα degradation and phosphorylation and reduced IKK activity in a dose-dependent manner. This study provides evidence that celecoxib suppresses the growth of GBM cell lines partly by inhibiting the NF-κB signaling pathway.
KW - Celecoxib
KW - Glioblastoma
KW - IKK
KW - IκBα
KW - NF-κB
KW - p50
KW - p65
UR - http://www.scopus.com/inward/record.url?scp=83055194567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83055194567&partnerID=8YFLogxK
U2 - 10.1007/s11060-011-0662-x
DO - 10.1007/s11060-011-0662-x
M3 - Article
C2 - 21847707
AN - SCOPUS:83055194567
SN - 0167-594X
VL - 106
SP - 99
EP - 109
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 1
ER -